UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000025473 |
|---|---|
| Receipt number | R000028899 |
| Scientific Title | Phase II study of VI (vincristine, irinotecan) / VPC (vincristine, pirarubicin, cyclophosphamide) / IE (ifosfamide, etoposide) / VAC (vincristine, actinomycin D, cyclophosphamide) for patients with newly diagnosed high-risk rhabdomyosarcoma. |
| Date of disclosure of the study information | 2017/02/01 |
| Last modified on | 2023/07/05 15:36:14 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Phase II study of VI (vincristine, irinotecan) / VPC (vincristine, pirarubicin, cyclophosphamide) / IE (ifosfamide, etoposide) / VAC (vincristine, actinomycin D, cyclophosphamide) for patients with newly diagnosed high-risk rhabdomyosarcoma.
Acronym
Phase II study of VI / VPC / IE / VAC for patients with newly diagnosed high-risk rhabdomyosarcoma.
Scientific Title
Phase II study of VI (vincristine, irinotecan) / VPC (vincristine, pirarubicin, cyclophosphamide) / IE (ifosfamide, etoposide) / VAC (vincristine, actinomycin D, cyclophosphamide) for patients with newly diagnosed high-risk rhabdomyosarcoma.
Scientific Title:Acronym
Phase II study of VI / VPC / IE / VAC for patients with newly diagnosed high-risk rhabdomyosarcoma.
Region
| Japan |
Condition
Condition
rhabdomyosarcoma
Classification by specialty
| Hematology and clinical oncology | Obstetrics and Gynecology | Pediatrics |
| Ophthalmology | Dermatology | Oto-rhino-laryngology |
| Orthopedics | Urology | Radiology |
| Oral surgery | Neurosurgery | Plastic surgery |
Classification by malignancy
Malignancy
Genomic information
YES
Objectives
Narrative objectives1
Determine the safety and efficacy of VAC 1.2 (Vincristine, Actinomycin D, Cyclophosphamide) therapy, VI (vincristine, irinotecan) therapy and interval-compressed therapy with VPC (Vincristine, Pirarubicin, Cyclophosphamide) therapy and IE (Ifosfamide, Etoposide) therapy for patients with high-risk rhabdomyosarcoma (Stage 2, 3, Group III alveolar rhabdomyosarcoma or Stage 4, Group IV embryonal and alveolar rhabdomyosarcoma).
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Phase II
Assessment
Primary outcomes
incidence of progressive disease until 54 weeks
Key secondary outcomes
response rate
time to treatment failure
overall survival
event free survival
frequency and grade of adverse event
cumulative days of each cycles of VPC therapy and IE therapy
cumulative dose of each chemotherapeutic agents of VPC therapy and IE therapy
frequency and grade of irinotecan-related adverse event in relation with UGT1A1 gene polymorphism
diagnostic and prognostic significance of serum miR-206 value
quality control of radiation therapy
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
chemotherapy 54 weeks
VAC1.2 therapy 4cycles
vincristine 1.5mg/m2 day 1
dactinomycin 0.045mg/kg day 1
cyclophosphamide 1.2g/m2 day1
VI therapy 6 cycles
vincristine 1.5mg/m2 day 1
irinotecan 50mg/m2 day 1-5
VPC therapy 5cycles
vincristine 1.5mg/m2 day 1
pirapubicin 30mg/m2 day 1,2
cyclophosphamide 1.2g/m2 day1
IE therapy 5cycles
ifosfamide 1800mg/m2 day 1-5
etopside 100mg/m2 day 1-5
surgery
radiotherapy
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| 30 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1) Histologically confirmed newly diagnosed rhabdomyosarcoma (RMS), meeting criteria for high-risk.
2) Age younger than 30 years old.
3) Initiation of chemotherapy within 42 days after first surgery.
4) No prior history of malignancy.
5) ECOG 0-2 (>=16 years old) or Lansky 50-100% (< 16 years old)
6) Patients must have sufficient organ function.
7) All patients and/or their parents or legal guardians must sign a written informed consent.
Key exclusion criteria
1) primary central nervous system rhabdomyosarcoma, positive findings of cerebrospinal fluid cytology, metastatic central nervous system rhabdomyosarcoma
2) patients with synchronous or metachronous concomitant malignancies
3) patients with Charcot-Marie-Tooth disease or varicella
4) patients with uncontrollable complications
Interstitial pneumonia, pulmonary fibrosis, severe emphysema
Uncontrollable diabetes mellitus
Uncontrollable hypertension
Severe electrocardiogram abnormality or clinically significant heart disease(heart failure, myocardial infarction, angina pectoris)
Liver failure, cirrhosis
Renal failure
5) patients with contraindication of drugs used in this study
6) Female patients who are pregnant or breastfeeding mother or patients considering pregnancy
7) Patients with any other inappropriate condition judged by physician
Target sample size
60
Research contact person
Name of lead principal investigator
| 1st name | Ogawa |
| Middle name | |
| Last name | Atsushi |
Organization
Niigata Cancer Center Hospital
Division name
Department of Pediatrics
Zip code
951-8566
Address
2-15-3 Kawagishi-cho, Niigata-city
TEL
025-266-5111
atsushi@niigata-cc.jp
Public contact
Name of contact person
| 1st name | Ogawa |
| Middle name | |
| Last name | Atsushi |
Organization
Niigata Cancer Center Hospital
Division name
Department of Pediatrics
Zip code
951-8566
Address
2-15-3 Kawagishi-cho, Niigata-city
TEL
025-266-5111
Homepage URL
atsushi@niigata-cc.jp
Sponsor or person
Institute
Japan Children's Cancer Group (JCCG)
Institute
Department
Personal name
Funding Source
Organization
Japan Agency for Medical Research and Development
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Ethics Review Board of Niigata Cancer Center Hospital
Address
2-15-3 Kawagishi-cho, Niigata-city 951-8566 Japan
Tel
025-266-5111
hosa@niigata-cc.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2017 | Year | 02 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2016 | Year | 11 | Month | 30 | Day |
Date of IRB
| 2022 | Year | 06 | Month | 09 | Day |
Anticipated trial start date
| 2017 | Year | 02 | Month | 01 | Day |
Last follow-up date
| 2026 | Year | 01 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2016 | Year | 12 | Month | 29 | Day |
Last modified on
| 2023 | Year | 07 | Month | 05 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028899
